Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice - PubMed (original) (raw)
. 1990 Sep 1;145(5):1615-20.
Affiliations
- PMID: 1974569
Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice
R B Alexander et al. J Immunol. 1990.
Abstract
We examined the long term survival of adoptively transferred, cultured tumor-infiltrating lymphocytes (TIL) in sublethally irradiated nontumor-bearing mice. TIL were produced by culturing Thy-1-enriched single cell suspensions from a variety of murine tumors in exogenous IL-2 along with irradiated tumor cells and splenocytes. TIL were adoptively transferred i.v. to mice and such animals demonstrated a statistically significant degree of protection from a subsequent i.v. tumor challenge. This protection lasted up to 6 wk and occurred in the absence of exogenous IL-2 administration in vivo. Using congenic B6.PL Thy-1 alpha/CY mice we demonstrated directly that TIL can survive in vivo for up to 6 wk and that the adoptively transferred TIL were the source of the relative immunity to subsequent tumor challenge. We conclude that TIL contain cells with substantial functional longevity in vivo even in the absence of exogenous IL-2. These studies are relevant to ongoing clinical trials of TIL as a therapy for patients with advanced cancer.
Similar articles
- Phenotypic characterization of murine tumor-infiltrating T lymphocytes.
Karpati RM, Banks SM, Malissen B, Rosenberg SA, Sheard MA, Weber JS, Hodes RJ. Karpati RM, et al. J Immunol. 1991 Mar 15;146(6):2043-51. J Immunol. 1991. PMID: 1672340 - Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK, Palmer LD, Perry-Lalley D, Bolton ES, Alexander RB, Horan PK, Yang JC, Muirhead KA. Wallace PK, et al. Cancer Res. 1993 May 15;53(10 Suppl):2358-67. Cancer Res. 1993. PMID: 8485722
Cited by
- Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC, Avram MF, Romoșan I, Cornianu M, Tăban S, Goldiș A. Lazăr DC, et al. World J Gastroenterol. 2018 Aug 28;24(32):3583-3616. doi: 10.3748/wjg.v24.i32.3583. World J Gastroenterol. 2018. PMID: 30166856 Free PMC article. Review. - In Vivo Murine-Matured Human CD3+ Cells as a Preclinical Model for T Cell-Based Immunotherapies.
Haworth KG, Ironside C, Norgaard ZK, Obenza WM, Adair JE, Kiem HP. Haworth KG, et al. Mol Ther Methods Clin Dev. 2017 May 17;6:17-30. doi: 10.1016/j.omtm.2017.05.004. eCollection 2017 Sep 15. Mol Ther Methods Clin Dev. 2017. PMID: 28649577 Free PMC article. - Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Subhash VV, Yeo MS, Tan WL, Yong WP. Subhash VV, et al. J Immunol Res. 2015;2015:308574. doi: 10.1155/2015/308574. Epub 2015 Oct 22. J Immunol Res. 2015. PMID: 26579545 Free PMC article. Review. - Gastric cancer and the epoch of immunotherapy approaches.
Niccolai E, Taddei A, Prisco D, Amedei A. Niccolai E, et al. World J Gastroenterol. 2015 May 21;21(19):5778-93. doi: 10.3748/wjg.v21.i19.5778. World J Gastroenterol. 2015. PMID: 26019442 Free PMC article. Review. - Immunotherapy in gastric cancer.
Matsueda S, Graham DY. Matsueda S, et al. World J Gastroenterol. 2014 Feb 21;20(7):1657-66. doi: 10.3748/wjg.v20.i7.1657. World J Gastroenterol. 2014. PMID: 24587645 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Miscellaneous